Targeting cardiac hypertrophy through a nuclear co‐repressor

Heart failure entails the inability of the heart to pump blood to vital organs. One of the main risk factors for heart failure is the development of pathological hypertrophy. In this issue of EMBO Molecular Medicine, Li and coworkers show that NCoR1, a co‐repressor of transcription factors, inhibits...

Descripción completa

Detalles Bibliográficos
Autores principales: Grund, Andrea, Heineke, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835198/
https://www.ncbi.nlm.nih.gov/pubmed/31622030
http://dx.doi.org/10.15252/emmm.201911297
Descripción
Sumario:Heart failure entails the inability of the heart to pump blood to vital organs. One of the main risk factors for heart failure is the development of pathological hypertrophy. In this issue of EMBO Molecular Medicine, Li and coworkers show that NCoR1, a co‐repressor of transcription factors, inhibits the transcriptional activity of MEF2 by stabilizing its complex with class II HDACs. By this mechanism, NCoR1 was identified as potent inhibitor of pathological cardiac hypertrophy and dysfunction.

Ejemplares similares